These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 12136618)

  • 21. Mode of initiation and ablation of ventricular fibrillation storms in patients with ischemic cardiomyopathy.
    Marrouche NF; Verma A; Wazni O; Schweikert R; Martin DO; Saliba W; Kilicaslan F; Cummings J; Burkhardt JD; Bhargava M; Bash D; Brachmann J; Guenther J; Hao S; Beheiry S; Rossillo A; Raviele A; Themistoclakis S; Natale A
    J Am Coll Cardiol; 2004 May; 43(9):1715-20. PubMed ID: 15120835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients.
    Daubert JP; Zareba W; Hall WJ; Schuger C; Corsello A; Leon AR; Andrews ML; McNitt S; Huang DT; Moss AJ;
    J Am Coll Cardiol; 2006 Jan; 47(1):98-107. PubMed ID: 16386671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of ventricular arrhythmias.
    Aronow WS
    Minerva Cardioangiol; 2010 Dec; 58(6):657-76. PubMed ID: 21135807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapeutic strategies in inappropriate ICD therapy].
    Klein G; Korte T
    Herz; 2005 Nov; 30(7):619-24. PubMed ID: 16333588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment approaches for patients with sustained VT/VF.
    Mitchell LB; Roy D
    Can J Cardiol; 2000 Jun; 16 Suppl C():23C-5C. PubMed ID: 10887274
    [No Abstract]   [Full Text] [Related]  

  • 26. Mechanisms, prediction and treatment of ventricular tachyarrhythmias occurring late after myocardial infarction.
    Denniss AR; Richards DA
    Heart Lung Circ; 2007 Jun; 16(3):156-61. PubMed ID: 17448725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs].
    Haverkamp W; Borggrefe M; Block M; Böcker D; Breithardt G
    Z Kardiol; 1996; 85 Suppl 6():97-106. PubMed ID: 9064989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
    Noseworthy PA; Rosenberg MA; Fifer MA; Palacios IF; Lowry PA; Ruskin JN; Sanborn DM; Picard MH; Vlahakes GJ; Mela T; Das S
    Am J Cardiol; 2009 Jul; 104(1):128-32. PubMed ID: 19576333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Radiofrequency ablation as acute treatment of ventricular arrhythmia].
    Emerek K; Riahi S; Hjortshøj SP
    Ugeskr Laeger; 2013 Jan; 175(1-2):48-51. PubMed ID: 23305641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of ventricular arrhythmias in structural heart disease.
    Jacobson JT; Iwai S; Aronow W
    Postgrad Med; 2015 Jun; 127(5):549-59. PubMed ID: 25971427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combining antiarrhythmic drugs and implantable devices therapy: benefits and outcome.
    Santini M; Pandozi C; Ricci R
    J Interv Card Electrophysiol; 2000 Jan; 4 Suppl 1():65-8. PubMed ID: 10590491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of antiarrhythmic drugs in patients with implantable cardioverter defibrillators.
    Van Herendael H; Pinter A; Ahmad K; Korley V; Mangat I; Dorian P
    Europace; 2010 May; 12(5):618-25. PubMed ID: 20304841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Ventricular tachyarrhythmias in patients without structural heart disease. Clinical and electrophysiologic characteristics of the tachyarrhythmias and long-term results of catheter ablation].
    Fiala M; Heinc P; Bulava A; Lukl J
    Vnitr Lek; 2001 Dec; 47(12):817-28. PubMed ID: 11826544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Assessment of ventricular arrhythmias].
    Osswald S; Rickenbacher P; Buser PT; Pfisterer M
    Praxis (Bern 1994); 1996 Feb; 85(7):179-87. PubMed ID: 8701182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interactions of antiarrhythmic drugs and implantable devices in controlling ventricular tachycardia and fibrillation.
    Rajawat YS; Dias D; Gerstenfeld EP; Dixit S; Shah B; Russo AM; Marchlinski FE
    Curr Cardiol Rep; 2002 Sep; 4(5):434-40. PubMed ID: 12169241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study.
    Grimm W; Christ M; Bach J; Müller HH; Maisch B
    Circulation; 2003 Dec; 108(23):2883-91. PubMed ID: 14623812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prognosis and management of patients with tachycardial heart arrhythmia ].
    Steinbach K
    Wien Med Wochenschr; 1984 Oct; 134(19-20):425-6. PubMed ID: 6516418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Ventricular arrhythmias : What has been confirmed in therapy?].
    Duncker D; Bauersachs J; Veltmann C
    Internist (Berl); 2017 Dec; 58(12):1272-1280. PubMed ID: 29071387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interactions between pharmacologic and nonpharmacologic antiarrhythmic therapy.
    Greene HL
    Am J Cardiol; 1996 Aug; 78(4A):61-6. PubMed ID: 8780330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of catheter ablation for ventricular tachycardia in patients with ischemic heart disease.
    El-Damaty A; Sapp JL
    Curr Opin Cardiol; 2011 Jan; 26(1):30-9. PubMed ID: 21119512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.